The deal is sealed. This week contracts were signed to make it official: ISA will move to the new BioPartner 5 building as soon as it is ready.
Over the past period we have been expanding and further growth is anticipated. We’re on a roll and rapidly outgrowing our current offices and lab space. Our collaboration with Regeneron for our lead asset ISA101b is booming and we are about to enter the clinic with other therapeutics in our pipeline.
To accommodate future expansion – in line with an aggressive growth strategy – we will move to a new building and double in